	US 12,410,223 B2
	TNF-alpha variant fusion molecules
Robin Allene Aglietti, South San Francisco, CA (US); Susannah Dale Barbee, San Francisco, CA (US); Peter Michael Bowers, La Jolla, CA (US); and Melanie Angelika Kleinschek, San Francisco, CA (US)
Assigned to TRex Bio, Inc., South San Francisco, CA (US)
Filed by TREX BIO, INC., South San Francisco, CA (US)
Filed on Nov. 8, 2024, as Appl. No. 18/942,121.
Application 18/942,121 is a continuation of application No. PCT/US2024/048933, filed on Sep. 27, 2024.
Claims priority of provisional application 63/586,809, filed on Sep. 29, 2023.
Prior Publication US 2025/0122256 A1, Apr. 17, 2025
Int. Cl. A61K 38/19 (2006.01); C07K 14/525 (2006.01); C12N 5/10 (2006.01); C12N 15/63 (2006.01); A61K 38/00 (2006.01)

CPC C07K 14/525 (2013.01) [A61K 38/191 (2013.01); C12N 5/10 (2013.01); C12N 15/63 (2013.01); A61K 38/00 (2013.01); C07K 2319/30 (2013.01)]

23 Claims

1. A TNF-alpha variant molecule comprising one or more TNF-alpha variants, wherein the one or more TNF-alpha variants comprises a polypeptide that specifically binds TNFR2 and comprises the amino acid sequence of SEQ ID NO: 9 or SEQ ID NO: 10.